3^rd International Conference and Expo on Biopharmaceutics and Biologic Drugs August 14-15, 2023 Singapore City, Singapore

Cindy Atwell is the Senior Vice President of Business Development and Alliance Management at Precision Pharma Bio Sciences, where she leads a team which forms new partnerships, manages current collaborations, and shapes new business processes as well as the portfolio. She holds approximately 22 years of experience in the pharmaceutical industry, with most of her time spent in business development and commercial roles. Over the course of her career, Cindy has led or participated in the negotiation of a number of transactions, totaling over $10Bn in value. Prior to Precision BioSciences, she led oncology and drug delivery deals as well as strategy projects at Halozyme. Over the years, Cindy has held various roles within the business development and commercial organizations at AbbVie, Amylin, and Impax. Early in her career, she participated in discovery research at a start-up biotechnology company. Cindy holds a BS in biochemistry and molecular biology from Pennsylvania State University and an MBA from the University of California, San Diego's Rady School of Management.

Biopharmaceutics and Biologic Drugs

Aida is the head of alliance management in oncology R&D at AstraZeneca. Her team is responsible for a broad portfolio of global strategic Alliances, including co-development, licensing, acquisitions, externalizations, and clinical collaborations. Aida has over 25 years of experience in the biopharma industry including project & portfolio management, alliance and integration management, business development, and compliance. At Medimmune she created and led a centralized alliance management function with accountability for key strategic partnerships across therapeutic areas. She was responsible along with her team for establishing innovative alliance best practices, advanced systems, and alliance capabilities at Medimmune. Prior to that during her 13 years at Medimmune, Aida held positions of increasing responsibility while managing a variety of drug development projects and partnerships across oncology, respiratory, inflammation, autoimmunity, and other therapeutic areas. Aida has experience leading through broad organization-wide change initiatives and has extensive drug development experience across diverse therapeutic areas gained through multiple roles earlier in her career. She fosters an alliance management community of excellence within AstraZeneca, is President of the DC/Mid Atlantic Chapter of the Association of Strategic Alliance Professionals, and CA-AM certified.

Pharma

Mary Beth is presently a director of alliance management at Vir Biotechnology and is a PhD physicist by training with experience across technology transfer, business development, and alliance management. At Vir, she is responsible for a portfolio of exploratory and early-stage research collaborations with academia, non-profit organizations, and biotech partners. Prior to joining Vir in 2021, Mary Beth led the Corporate Partnerships team at the California Institute of Technology (Caltech), where she was responsible for developing, maintaining, and augmenting research partnerships and strategic relationships between Caltech and industry collaborators. She began her career in science policy, focusing on innovation policy and program evaluation. A registered U.S. Patent Agent, Campbell was awarded the 2013 Association of University Technology Managers (AUTM) Howard Bremer Scholarship for new technology transfer professionals. Mary Beth was a national defense science and engineering graduate fellow while earning her PhD in applied physics from Harvard University.

Pharmaceutical

Patrick Gliha is an executive director and member of the BMS Global Alliances Leadership Team. In this role, Patrick is responsible for leading a team of seven alliance managers and overseeing a portfolio of external collaborations that are cross-therapeutic, cross-modality, and cross-phases of development and commercialization. Patrick joined BMS in 2019 through the acquisition of Celgene. Prior to joining the global alliances team, he began his career working in global government affairs & policy at Celgene and Amgen, working on access and reimbursement for the in-line portfolio and late-stage pipeline.

Biopharma

Brent leads teams focused on maximizing the value of partnered assets at each stage of the development and commercialization cycle. Brent has played an integral role in some of the largest development and commercial alliances at Lilly, including worldwide partnerships with BMS, Merck KGaA, Daiichi-Sankyo, Innovent Biologics, GSK, and Sanofi. He also has alliance manager experience with venture capital collaborations, strategic equity investment companies, and oncology clinical trial collaborations. Brent has responsibilities for M&A integration as well. Brent has an engineering degree from Purdue and an MBA from Indiana University. He also has a CA-AM and is a certified management accountant (CMA).

Biologic Drugs

Sreenivasan Sasidharan has completed his PhD from Universiti Sains Malaysia in 2007. He is the Associate Professor in Institute for Research in Molecular Medicine of Universiti Sains Malaysia, a public University in Malaysia. He has over 160 publications with total impact factor of 175, multiple book chapters, significant grant support, and over 100 posters/abstracts at national and international meetings as well as Organizer, Keynote, Invited Speaker and chair of International & National Congresses. Has been serving as an Editorial Board Member and Reviewer of international journals. He reviewed more than 100 manuscript for international journal.

His research interests include medicinal plants and their role in Health and Disease Management, Molecular Mechanisms and Biology of Free Radicals, miRNA, Anticancer, Antioxidants, Antimicrobial and also isolations and identification of phytochemicals from local natural resources for various biotechnology purposes including green synthesis of gold nanoparticle. He also graduated more than 15 post graduate student as main supervisor.

Gautam Sethi has completed his Postdoctoral training at University of Texas MD Anderson Cancer Center and joined Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore in 2008 as an Assistant Professor and was promoted to Associate Professor in 2015. The focus of his research over the past few years has been to elucidate the mechanism(s) of activation of oncogenic transcription factors such as NF-kB/STAT3 by carcinogens and inflammatory agents and the identification of novel inhibitors of these proteins for prevention of and therapy for cancer. He has more than 150 scientific publications in high impact factor peer reviewed journals and has several international awards to his credit. He currently serves as an Academic Editor for PLOSONE, Editorial Board Member of Scientific Reports and ad-hoc Reviewer for several other international journals.

Drug Development, Pharmacology and Drug analysis

James (Jim) Mullen joined the Editas medicine board of directors as chairman in March 2018 and in February 2021 was appointed as President and CEO. In June 2022, Jim became Executive Chairman. Jim is a recognized biotech leader with more than 40 years of experience building leading biotechnology and pharmaceutical organizations on a global scale. Previously, he served as chief executive officer of Patheon NV, a leading global provider of pharmaceutical development and manufacturing services, until its acquisition by Thermo Fisher Scientific, Inc. (Thermo Fisher), in August 2017. Before joining Patheon, Jim served as chief executive officer and president at Biogen, Inc. (Biogen), one of the world's largest biotechnology companies. Prior to being named chief executive officer, he held various operating positions at Biogen, including chief operating officer, vice president, international, and vice president, operations. Jim also serves on the board of directors of Thermo Fisher Scientific. He previously served on the board of directors of Patheon, Biogen, and PerkinElmer, Inc. He was also chairman of the board of directors of the Biotechnology Innovation Organization. Jim holds a BS in chemical engineering from Rensselaer Polytechnic Institute and an MBA from Villanova University.

Biopharma

Prakash Raman has served as Ribon’s president, chief executive officer and board member since February 2022. Dr. Raman brings to Ribon decades of biopharmaceutical business development and executive leadership experience, blending his scientific background, program and portfolio management and strong business development experience. Prior to joining Ribon, he served as Senior Partner, Chief Business Development Officer at Flagship Pioneering from October 2019 to February 2022, where he leveraged the platforms and assets in Flagship’s network to generate opportunities for significant value creation. Prior to Flagship, Dr. Raman spent nearly fourteen years at Novartis, most recently as Vice President, Global Head of Novartis Institutes for Biomedical Research (NIBR) Business Development and Licensing (BD&L). During his time at Novartis, Dr. Raman was instrumental in forging key collaborations in immuno-oncology, executing many out-licensing opportunities and guiding the acquisitions of Advanced Accelerator Applications, Endocyte, IFM Tre and Selexys. In addition, he has led cross-functional drug discovery and early development project teams that successfully progressed compounds to clinical testing in patients. Prior to Novartis, Dr. Raman spent six years as a Senior Scientist at Millennium Pharmaceuticals and two years as a post-doctoral fellow at The Scripps Research Institute. He completed his undergraduate work at the Indian Institute of Technology, Bombay, and received his Ph.D. in Organic and Medicinal Chemistry from the University of Wisconsin-Madison.

Biopharma Drugs , Chemistry

Katherine Kendrick is Head of Alliance Management at Jazz Pharmaceuticals, a global biopharmaceutical company that develops life-changing medicines for people with serious diseases, who often have limited or no options. Katherine leads the Jazz Alliance Management team and department, delivering alliance portfolio management and value for global partnerships in development and commercial life cycle phases. Prior to joining Jazz in 2019, Katherine was with Eli Lilly & Company and Elanco Animal Health, where she established and led the Alliance Management organization. For more than 20 years, Katherine has focused on global clinical development and strategic alliance partnering in the human and animal health pharmaceutical sector. She is passionate about building and optimizing alliance teams and advising alliance leaders, enabling challenging decision-making with a patient focused, alliance value driven approach. Katherine holds a BS in Biomedical Science from Texas A&M University and has been an active member of ASAP since 2011. It's not all about work for Katherine–in her personal time, she is a veterinary nursing student at Purdue University and volunteers with the veterinary team for Save Elephant Foundation in Thailand, rescuing and rehabilitating endangered Asian Elephants

biopharmaceutical